Positron claimed that facilitated by the increase in reimbursement for cardiac PET and an industry-wide movement for more efficient medical imaging, Positron’s Attrius has seen more interest and sales. As a result of the recent sales, Positron has met its six month projections and has to increase production earlier than previous estimations.

Based on Positron’s current sales and pipeline, Positron believes that they will surpass 2010 and 2011 targets of approximately 70 systems in the next 18 months.

Positron utilises its proprietary product line to provide solutions to the nuclear medicine community ranging from imaging to radiopharmaceutical distribution.